Literature DB >> 30755436

C/EBPβ is a critical mediator of IFN-α-induced exhaustion of chronic myeloid leukemia stem cells.

Asumi Yokota1,2, Hideyo Hirai1, Ryuichi Sato3, Hiroko Adachi3, Fumiko Sato3, Yoshihiro Hayashi2,4, Atsushi Sato1, Naoka Kamio1, Yasuo Miura1, Masakazu Nakano3, Daniel G Tenen5,6, Shinya Kimura7, Kei Tashiro3, Taira Maekawa1.   

Abstract

Even in the era of ABL tyrosine kinase inhibitors, eradication of chronic myeloid leukemia (CML) stem cells is necessary for complete cure of the disease. Interferon-α (IFN-α) has long been used for the treatment of chronic-phase CML, but its mechanisms of action against CML stem cells remain unclear. We found that IFN-α upregulated CCAAT/enhancer binding protein β (C/EBPβ) in BCR-ABL-expressing mouse cells by activating STAT1 and STAT5, which were recruited to a newly identified 3' distal enhancer of Cebpb that contains tandemly aligned IFN-γ-activated site elements. Suppression or deletion of the IFN-γ-activated site elements abrogated IFN-α-dependent upregulation of C/EBPβ. IFN-α induced differentiation and exhaustion of CML stem cells, both in vitro and in vivo, in a C/EBPβ-dependent manner. In addition, IFN-α upregulated C/EBPβ and induced exhaustion of lineage- CD34+ cells from CML patients. Collectively, these results clearly indicate that C/EBPβ is a critical mediator of IFN-α-induced differentiation and exhaustion of CML stem cells.
© 2019 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30755436      PMCID: PMC6373744          DOI: 10.1182/bloodadvances.2018020503

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  69 in total

1.  Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining.

Authors:  J D Rowley
Journal:  Nature       Date:  1973-06-01       Impact factor: 49.962

2.  Interferon γ is a STAT1-dependent direct inducer of BCL6 expression in imatinib-treated chronic myeloid leukemia cells.

Authors:  H S Madapura; N Nagy; D Ujvari; T Kallas; M C L Kröhnke; S Amu; M Björkholm; L Stenke; P K Mandal; J S McMurray; M Keszei; L S Westerberg; H Cheng; F Xue; G Klein; E Klein; D Salamon
Journal:  Oncogene       Date:  2017-04-03       Impact factor: 9.867

3.  Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia.

Authors:  Andreas Burchert; Martin C Müller; Philippe Kostrewa; Philipp Erben; Tilman Bostel; Simone Liebler; Rüdiger Hehlmann; Andreas Neubauer; Andreas Hochhaus
Journal:  J Clin Oncol       Date:  2010-02-08       Impact factor: 44.544

4.  Hematopoietic Stem Cells Are the Major Source of Multilineage Hematopoiesis in Adult Animals.

Authors:  Catherine M Sawai; Sonja Babovic; Samik Upadhaya; David J H F Knapp; Yonit Lavin; Colleen M Lau; Anton Goloborodko; Jue Feng; Joji Fujisaki; Lei Ding; Leonid A Mirny; Miriam Merad; Connie J Eaves; Boris Reizis
Journal:  Immunity       Date:  2016-08-30       Impact factor: 31.745

5.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

Authors:  B J Druker; M Talpaz; D J Resta; B Peng; E Buchdunger; J M Ford; N B Lydon; H Kantarjian; R Capdeville; S Ohno-Jones; C L Sawyers
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

6.  IFNalpha activates dormant haematopoietic stem cells in vivo.

Authors:  Marieke A G Essers; Sandra Offner; William E Blanco-Bose; Zoe Waibler; Ulrich Kalinke; Michel A Duchosal; Andreas Trumpp
Journal:  Nature       Date:  2009-02-11       Impact factor: 49.962

7.  Interactions among HCLS1, HAX1 and LEF-1 proteins are essential for G-CSF-triggered granulopoiesis.

Authors:  Julia Skokowa; Maxim Klimiankou; Olga Klimenkova; Dan Lan; Kshama Gupta; Kais Hussein; Esteban Carrizosa; Inna Kusnetsova; Zhixiong Li; Claudio Sustmann; Arnold Ganser; Cornelia Zeidler; Hans-Heinrich Kreipe; Janis Burkhardt; Rudolf Grosschedl; Karl Welte
Journal:  Nat Med       Date:  2012-09-23       Impact factor: 53.440

8.  Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo.

Authors:  Chen Zhao; Jordan Blum; Alan Chen; Hyog Young Kwon; Seung Hye Jung; J Michael Cook; Anand Lagoo; Tannishtha Reya
Journal:  Cancer Cell       Date:  2007-12       Impact factor: 31.743

9.  Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia.

Authors:  Andreas Burchert; Stefan Wölfl; Manuel Schmidt; Cornelia Brendel; Barbara Denecke; Dali Cai; Larissa Odyvanova; Tanja Lahaye; Martin C Müller; Thomas Berg; Harald Gschaidmeier; Burghardt Wittig; Rüdiger Hehlmann; Andreas Hochhaus; Andreas Neubauer
Journal:  Blood       Date:  2002-06-28       Impact factor: 22.113

10.  Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia.

Authors:  Chen Zhao; Alan Chen; Catriona H Jamieson; Mark Fereshteh; Annelie Abrahamsson; Jordan Blum; Hyog Young Kwon; Jynho Kim; John P Chute; David Rizzieri; Michael Munchhof; Todd VanArsdale; Philip A Beachy; Tannishtha Reya
Journal:  Nature       Date:  2009-04-09       Impact factor: 49.962

View more
  5 in total

1.  Targeting UPR signaling pathway by dasatinib as a promising therapeutic approach in chronic myeloid leukemia.

Authors:  Buket Ozel; Sezgi Kipcak; Cigir Biray Avci; Maryam Sabour Takanlou; Leila Sabour Takanlou; Burcin Tezcanli Kaymaz; Ilknur Karatekin; Cumhur Gunduz; Nur Selvi Gunel
Journal:  Med Oncol       Date:  2022-06-18       Impact factor: 3.064

Review 2.  Yin and Yang: The dual effects of interferons on hematopoiesis.

Authors:  Yasmin Demerdash; Bailee Kain; Marieke A G Essers; Katherine Y King
Journal:  Exp Hematol       Date:  2021-02-08       Impact factor: 3.084

3.  C/EBPβ isoforms sequentially regulate regenerating mouse hematopoietic stem/progenitor cells.

Authors:  Atsushi Sato; Naoka Kamio; Asumi Yokota; Yoshihiro Hayashi; Akihiro Tamura; Yasuo Miura; Taira Maekawa; Hideyo Hirai
Journal:  Blood Adv       Date:  2020-07-28

4.  TRAF6 functions as a tumor suppressor in myeloid malignancies by directly targeting MYC oncogenic activity.

Authors:  Tomoya Muto; Maria Guillamot; Jennifer Yeung; Jing Fang; Joshua Bennett; Bettina Nadorp; Audrey Lasry; Luna Zea Redondo; Kwangmin Choi; Yixiao Gong; Callum S Walker; Kathleen Hueneman; Lyndsey C Bolanos; Laura Barreyro; Lynn H Lee; Kenneth D Greis; Nikita Vasyliev; Alireza Khodadadi-Jamayran; Evgeny Nudler; Amaia Lujambio; Scott W Lowe; Iannis Aifantis; Daniel T Starczynowski
Journal:  Cell Stem Cell       Date:  2022-01-18       Impact factor: 25.269

Review 5.  Chronic myeloid leukemia stem cells: targeting therapeutic implications.

Authors:  Hanieh Mojtahedi; Niloufar Yazdanpanah; Nima Rezaei
Journal:  Stem Cell Res Ther       Date:  2021-12-18       Impact factor: 6.832

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.